S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells

Skp2 (S-phase kinase-associated protein 2) plays an oncogenic role in a variety of human cancers. However, the function of Skp2 in osteosarcoma (OS) is elusive. Therefore, in the current study, we explore whether Skp2 exerts its oncogenic function in OS. The cell growth, apoptosis, invasion and cell...

Full description

Saved in:
Bibliographic Details
Published in:Cell cycle (Georgetown, Tex.) Tex.), 2017-08, Vol.16 (16), p.1547-1555
Main Authors: Ding, Lu, Li, Rong, Sun, Rongxin, Zhou, Yang, Zhou, Yubo, Han, Xiaoping, Cui, Yong, Wang, Wu, Lv, Qing, Bai, Jingping
Format: Article
Language:English
Subjects:
Apoptosis - genetics
Cell Cycle - genetics
Cell Line, Tumor
Cell Movement - genetics
Cell Proliferation - genetics
Gene Expression Regulation, Neoplastic
Humans
Neoplasm Invasiveness
Osteosarcoma - genetics
Osteosarcoma - metabolism
Osteosarcoma - pathology
S-Phase Kinase-Associated Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Skp2 (S-phase kinase-associated protein 2) plays an oncogenic role in a variety of human cancers. However, the function of Skp2 in osteosarcoma (OS) is elusive. Therefore, in the current study, we explore whether Skp2 exerts its oncogenic function in OS. The cell growth, apoptosis, invasion and cell cycle were measured in OS cells after Skp2 overexpression. We found that overexpression of Skp2 enhanced cell growth, and inhibited cell apoptosis in OS cells. Moreover, we observed that upregulation of Skp2 accelerated cell cycle progression in OS cells. Furthermore, the ability of migration and invasion was enhanced in Skp2 overexpressing OS cells. Mechanically, our Western blotting data suggested that Skp2 decreased the expression of E-cadherin, Foxo1, p21, and p57, but increased MMP-9 in OS cells. In conclusion, our study demonstrated that Skp2 exhibited an oncogenic function in OS cells, suggesting that inhibition of Skp2 may be a novel approach for the treatment of OS.
ISSN:1538-4101
1551-4005
DOI:10.1080/15384101.2017.1346760